PW Medtech Group
Market Cap
HK$1.8b
Last Updated
2019/10/15 12:49 UTC
Data Sources
Company Financials +
Executive Summary
PW Medtech Group Limited, an investment holding company, operates as a medical device company in the People’s Republic of China.
Snowflake
Fundamentals
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has PW Medtech Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-6.5%
1358
1.5%
HK Medical Equipment
2.9%
HK Market
1 Year Return
-21.8%
1358
8.3%
HK Medical Equipment
0.7%
HK Market
Return vs Industry: 1358 underperformed the Hong Kong Medical Equipment industry which returned 8.3% over the past year.
Return vs Market: 1358 underperformed the Hong Kong Market which returned 0.7% over the past year.
Shareholder returns
| 1358 | Industry | Market | |
|---|---|---|---|
| 7 Day | -6.5% | 1.5% | 2.9% |
| 30 Day | 13.9% | -0.9% | -2.5% |
| 90 Day | 18.6% | 19.0% | -5.4% |
| 1 Year | -21.8%-21.8% | 9.5%8.3% | 4.4%0.7% |
| 3 Year | -53.6%-53.6% | 12.1%8.6% | 17.0%5.2% |
| 5 Year | -76.0%-76.0% | 2.1%-2.9% | 20.2%0.2% |
Price Volatility Vs. Market
How volatile is PW Medtech Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Here's Why PW Medtech Group (HKG:1358) Has A Meaningful Debt Burden2 weeks ago | Simply Wall St
If You Had Bought PW Medtech Group (HKG:1358) Stock Five Years Ago, You'd Be Sitting On A 72% Loss, Today1 month ago | Simply Wall St
Do Directors Own PW Medtech Group Limited (HKG:1358) Shares?Valuation
Is PW Medtech Group undervalued compared to its fair value and its price relative to the market?
11.92x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate 1358's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate 1358's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1358 is good value based on its PE Ratio (11.9x) compared to the Medical Equipment industry average (15.7x).
PE vs Market: 1358 is poor value based on its PE Ratio (11.9x) compared to the Hong Kong market (10.4x).
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate 1358's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1358 is good value based on its PB Ratio (0.4x) compared to the HK Medical Equipment industry average (1.6x).
Next Steps
Future Growth
How is PW Medtech Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
15.3%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PW Medtech Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of 1358’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- PW Medtech Group competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has PW Medtech Group performed over the past 5 years?
-22.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 1358's earnings have declined by -22.2% per year over the past 5 years.
Accelerating Growth: 1358's earnings growth over the past year (404.5%) exceeds its 5-year average (-22.2% per year).
Earnings vs Industry: 1358 earnings growth over the past year (404.5%) exceeded the Medical Equipment industry 50.2%.
Return on Equity
High ROE: 1358's Return on Equity (3%) is considered low.
Return on Assets
ROA vs Industry: 1358's Return on Assets is below or equal to the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: 1358's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is PW Medtech Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1358's short term assets (CN¥392.8M) do not cover its short term liabilities (CN¥691.2M)
Long Term Liabilities: 1358's short term assets (392.8M) exceeds its long term liabilities (8.2M)
Debt to Equity History and Analysis
Debt Level: 1358's debt to equity ratio (12.7%) is considered satisfactory
Reducing Debt: 1358's debt to equity ratio has reduced from 13.8% to 12.7% over the past 5 years.
Debt Coverage: 1358's debt is not well covered by operating cash flow (14.4%).
Interest Coverage: 1358's interest payments on its debt are not well covered by EBIT (2x coverage).
Balance Sheet
Inventory Level: 1358 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 1358's debt is not covered by short term assets (assets are 0.7x debt).
Next Steps
Dividend
What is PW Medtech Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate 1358's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 1358's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if 1358's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1358's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1358's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
What is the CEO of PW Medtech Group's salary, the management and board of directors tenure and is there insider trading?
6.0yrs
Average board tenure
CEO
Yue'e Zhang (56yo)
0.6yrs
Tenure
CN¥995,000
Compensation
Ms. Yue'e Zhang has been Chief Executive Officer at PW Medtech Group Ltd. since March 31, 2019. Ms. Zhang serves as a General Manager, Senior Engineer and Executive Director of WP Medical Technologies, Inc ...
CEO Compensation Analysis
Compensation vs. Market: Yue'e has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Hong Kong market.
Compensation vs Earnings: Yue'e's compensation has been consistent with company performance over the past year.
Board Age and Tenure
6.0yrs
Average Tenure
54yo
Average Age
Experienced Board: 1358's board of directors are considered experienced (6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 28,000,000 |
| Max Price | CN¥1.21 |
Ownership Breakdown
Management Team
Yue'e Zhang (56yo)
Chairman & CEO
- Tenure: 0.6yrs
- Compensation: CN¥995.00k
Lingyan Ding (31yo)
Financial Director
- Tenure: 0yrs
Tin Yu Wong
Company Secretary
- Tenure: 0.3yrs
Board Members
Xiaogang Wang (46yo)
Independent Non-Executive Director
- Tenure: 6yrs
- Compensation: CN¥169.00k
Geng Chen (48yo)
Independent Non-Executive Director
- Tenure: 6yrs
- Compensation: CN¥169.00k
Xingdong Zhang (81yo)
Independent Non-Executive Director
- Tenure: 6yrs
- Compensation: CN¥169.00k
Liwei Jiang (52yo)
Non-Executive Director
- Tenure: 6.3yrs
- Compensation: CN¥1.61m
Junshan Lin (57yo)
Non-Executive Director
- Tenure: 6.3yrs
- Compensation: CN¥300.00k
Yue'e Zhang (56yo)
Chairman & CEO
- Tenure: 0.6yrs
- Compensation: CN¥995.00k
Company Information
PW Medtech Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: PW Medtech Group Limited
- Ticker: 1358
- Exchange: SEHK
- Founded: 2011
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: HK$1.820b
- Shares outstanding: 1.57b
- Website: https://www.pwmedtech.com
Number of Employees
Location
- PW Medtech Group Limited
- Building 1, Courtyard 23
- Panlong West Road
- Beijing
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1358 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Nov 2013 |
| PWE | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Nov 2013 |
Biography
PW Medtech Group Limited, an investment holding company, operates as a medical device company in the People’s Republic of China. It manufactures and sells infusion sets, such as non-PVC-based infusion sets ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/15 12:49 |
| End of Day Share Price | 2019/10/15 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.